Why Wait? Investors Can Expect a More Proactive, Aggressive FDA
This article was originally published in RPM Report
Comments made by former FDA offi cials and incoming leadership describe a scenario of nearcrisis and rock-bottom morale. Agency management is taking aggressive action to address those concerns. Investors have zeroed in on the new Commissioner(s).
You may also be interested in...
While Barr's attempt to switch the emergency contraceptive Plan B to over-the-counter status is immaterial to the company, the rest of the drug industry can't afford to ignore the controversy, which could jeopardize the renewal of crucial legislation that supports fast and predictable reviews of all new drugs. Moreover, FDA may be reopening old controversies, like whether third parties can force an OTC switch against a brand company's wishes.
The intensely negative advisory committee for Biogen’s proposed Alzheimer’s therapy was a shocker. Would it have happened if US FDA had been able to convene an in-person event instead of a ‘virtual’ one?
With landmark advisory committee meetings coming up, we take a look back at some of the memorable panel meetings over the last 20 years.